» Articles » PMID: 11306728

Hepatotoxicity of Chemotherapy

Overview
Journal Oncologist
Specialty Oncology
Date 2001 Apr 18
PMID 11306728
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.

Citing Articles

Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review).

Ding Y, Yu Y Mol Med Rep. 2025; 31(4).

PMID: 40017144 PMC: 11884236. DOI: 10.3892/mmr.2025.13474.


Toxicology study of a tissue anchoring paclitaxel prodrug.

Chinthapatla R, Stephens J, Neumann-Rivera I, Henderson N, Nie M, Haynes H BMC Pharmacol Toxicol. 2024; 25(1):92.

PMID: 39639360 PMC: 11619278. DOI: 10.1186/s40360-024-00819-6.


Levocabastine ameliorates cyclophosphamide-induced hepatotoxicity in Swiss albino mice: modulation of Nrf2, NF-κB p65, cleaved caspase-3 and TGF-β signaling molecules.

Akram W, Najmi A, Haque S J Mol Histol. 2024; 56(1):3.

PMID: 39602021 DOI: 10.1007/s10735-024-10286-2.


Modeling Tumor Cell Dormancy in an Ex Vivo Liver Metastatic Niche.

McDonald J, Clark A Methods Mol Biol. 2024; 2811:37-53.

PMID: 39037648 DOI: 10.1007/978-1-0716-3882-8_3.


STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition.

Jiang X, Luo T, Yang K, Lee M, Liu J, Tillman L Sci Adv. 2024; 10(29):eado0082.

PMID: 39018400 PMC: 466951. DOI: 10.1126/sciadv.ado0082.